CN103142702A - 治疗猪蓝耳病的中草药注射液及其制备方法 - Google Patents
治疗猪蓝耳病的中草药注射液及其制备方法 Download PDFInfo
- Publication number
- CN103142702A CN103142702A CN2013100916831A CN201310091683A CN103142702A CN 103142702 A CN103142702 A CN 103142702A CN 2013100916831 A CN2013100916831 A CN 2013100916831A CN 201310091683 A CN201310091683 A CN 201310091683A CN 103142702 A CN103142702 A CN 103142702A
- Authority
- CN
- China
- Prior art keywords
- chinese herbal
- herbal medicine
- injection
- parts
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 48
- 239000007924 injection Substances 0.000 title claims abstract description 48
- 241000411851 herbal medicine Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000007788 liquid Substances 0.000 title claims description 22
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 title description 7
- 208000032625 disorder of ear Diseases 0.000 claims abstract description 24
- 235000014134 echinacea Nutrition 0.000 claims abstract description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 4
- 241001061264 Astragalus Species 0.000 claims abstract 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract 5
- 235000006533 astragalus Nutrition 0.000 claims abstract 5
- 210000004233 talus Anatomy 0.000 claims abstract 5
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 244000133098 Echinacea angustifolia Species 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 6
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 241000555712 Forsythia Species 0.000 claims 4
- 239000008215 water for injection Substances 0.000 claims 4
- 239000012141 concentrate Substances 0.000 claims 3
- 240000004530 Echinacea purpurea Species 0.000 claims 2
- 238000010411 cooking Methods 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 20
- 241000894006 Bacteria Species 0.000 abstract description 6
- 241000555682 Forsythia x intermedia Species 0.000 abstract description 2
- 241000258180 Echinacea <Echinodermata> Species 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 28
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 239000009636 Huang Qi Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- -1 aldoketones Chemical class 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- QUAPPCXFYKSDSV-LBPRGKRZSA-N (2s)-5,7-dihydroxy-6-methoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2OC3=CC(O)=C(C(=C3C(=O)C2)O)OC)=CC=CC=C1 QUAPPCXFYKSDSV-LBPRGKRZSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000202347 Porcine circovirus Species 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- 229940051027 pasteurella multocida Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000012153 swine disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-VIFPVBQESA-N (R)-(+)-alpha-terpineol Chemical compound CC1=CC[C@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- CPGCVOVWHCWVTP-LJAQVGFWSA-N (S)-nonacosan-10-ol Chemical compound CCCCCCCCCCCCCCCCCCC[C@@H](O)CCCCCCCCC CPGCVOVWHCWVTP-LJAQVGFWSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- JCBLOUSNKOCZTD-UHFFFAOYSA-N 4-hydroxy-3-(2-methylprop-1-enyl)naphthalene-1,2-dione Chemical compound C1=CC=C2C(=O)C(=O)C(C=C(C)C)=C(O)C2=C1 JCBLOUSNKOCZTD-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- WSVZNLLZVLACNC-UHFFFAOYSA-N CC1(C(CCC(O1)(C)O)C=C)C Chemical compound CC1(C(CCC(O1)(C)O)C=C)C WSVZNLLZVLACNC-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 229930191995 Dihydrooroxylin Natural products 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 241000134874 Geraniales Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001423398 Ruscus hypoglossum Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- HKOIDIVCPUDLBS-UHFFFAOYSA-N Skullcapflavone II Natural products Oc1cccc(O)c1C2=CC(=O)c3c(O)c(O)c(O)c(O)c3O2 HKOIDIVCPUDLBS-UHFFFAOYSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 150000007822 carvacrol derivatives Chemical class 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- CPGCVOVWHCWVTP-UHFFFAOYSA-N celidoniol Natural products CCCCCCCCCCCCCCCCCCCC(O)CCCCCCCCC CPGCVOVWHCWVTP-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- HXRBQSOSCSKMTM-UHFFFAOYSA-N nor-lapachol Natural products C1=CC=C2C(=O)C(C=C(C)C)=C(O)C(=O)C2=C1 HXRBQSOSCSKMTM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DJHDOMQWAUJNKX-UHFFFAOYSA-N phillygenin Natural products COc1ccc(cc1O)C2OCC3C2COC3c4ccc(OC)c(OC)c4 DJHDOMQWAUJNKX-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940056692 resinol Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- GMQFOKBGMKVUQZ-UHFFFAOYSA-N scullcapflavone II Chemical compound COC1=CC=CC(O)=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1 GMQFOKBGMKVUQZ-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- CPJKKWDCUOOTEW-UHFFFAOYSA-N sylvatesmin Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(O)=CC=3)C2CO1 CPJKKWDCUOOTEW-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗猪蓝耳病的中草药注射液及其制备方法,该中草药注射液由下述重量配比的原料药制成:金银花1-2份,连翘2-4份,黄芩1-2份,紫锥菊6-8份,黄芪4-6份。上述原料经过粉碎,配料,三次水煮浸提,合并三次滤液,浓缩后醇沉,调pH,活性炭脱色,吐温-80助溶,按定量加入防腐剂,搅匀,过滤,灌装,灭菌,制成本发明治疗猪蓝耳病的中草药注射液。本发明中草药注射液对治疗猪蓝耳病有很好的效果。
Description
技术领域
本发明涉及治疗猪病用的中草药制剂,具体涉及一种治疗猪蓝耳病的中草药注射液及其制备方法。
背景技术
猪蓝耳病即猪繁殖与呼吸综合征(PRRS)是由猪繁殖与呼吸综合征病毒(PRRSV)引起的猪的一种高度接触性传染病,不同年龄、品种和性别的猪均能感染,但以妊娠母猪和1月龄以内的仔猪最易感染。该病以母猪流产、死胎、弱胎、木乃伊胎以及仔猪呼吸困难、败血症、高死亡率等为主要特征。因发病时部分病猪的特征表现是耳部发紫,故该病又称为“猪蓝耳病”。近年来普遍流行的高致病性猪蓝耳病,是由PRRSV变异株引起的一种急性高致死性传染病,仔猪发病率可达100%、死亡率可达50%以上,母猪流产率可达30%以上,育肥猪也可发病及死亡;PRRSV感染后,首先在局部的易感巨噬细胞中复制,然后迅速向全身淋巴组织和肺扩散,有时也向其他组织扩散。病毒在细胞内增殖,使巨噬细胞破裂,溶解崩溃造成巨噬细胞数量减少,肺泡壁增厚,淋巴组织呈衰竭状态,肺泡巨噬细胞对其他细菌和病毒疫苗的免疫力降低,易继发感染猪瘟病毒(CSFV)、多杀性巴氏杆菌(PM)、链球菌(SS)、猪副嗜血杆菌(HP)、放线杆菌(AS)、支原体(MHR)、圆环病毒(PCV-2)等,这是本病与其他疾病混合或继发感染的根本原因。同时因为毒株的变异导致免疫细胞识别能力降低,而逃避抗体的中和及细胞毒性T细胞的杀伤作用。因此,有效的防治猪蓝耳病的治则是:清热解毒,抗菌消炎,激活免疫系统,恢复巨噬细胞功能,抑制病毒繁殖,促进巨噬细胞摄取、处理和传递抗原,调节和增强T/B细胞的反应能力、增加T/B细胞的数量及促进其发育成熟,使猪在接种疫苗后能获得高水平的免疫应答反应。目前,化学药物增强机体免疫力都不同程度地存在着毒副作用、药物残留和阶段性用药达不到理想效果的弊端。中草药属于天然、绿色药物,对动物及人类安全、无毒副作用,并且能从根本上调节机体免疫功能。目前中草药制剂的研究有了较大发展,治疗猪病的兽用中草药种类也较多,但能够有效治疗猪蓝耳病的中草药注射液尚未见有报道。
发明内容
本发明的目的在于针对上述问题,提供一种能够有效治疗猪蓝耳病的中草药注射液。
本发明的目的还在于提供该中草药注射液的制备方法。
本发明的技术方案是:一种治疗猪蓝耳病的中草药注射液,它是由下述重量配比的原料药制成:金银花1-2份,连翘2-4份,黄芩1-2份,紫锥菊6-8份,黄芪4-6份。
本发明治疗猪蓝耳病的中草药注射液优选的原料药重量配比是:金银花2份,连翘4份,黄芩2份,紫锥菊7份,黄芪5份。
本发明治疗猪蓝耳病的中草药注射液的制备方法包括以下步骤:
(1)按重量配比分别称取金银花、连翘、黄芩、紫锥菊、黄芪中草药饮片,并分别粉碎成中草药粗粉;
(2)取黄芩、黄芪中草药粗粉,按步骤(1)得到的中草药粗粉总重量的7倍加注射水浸泡1-1.5h,加热煎煮25-35min,再加入金银花、连翘、紫锥菊中草药粗粉煎煮25-35 min,倾出第一次煮液,再按步骤(1)得到的中草药粗粉总重量的5倍加注射水煎煮两次,每次煎煮25-35min,得到第二次煮液和第三次煮液;
(3)合并步骤(2)得到的三次煮液,过滤,浓缩至每毫升注射水含生药1g,得到浓缩煮液;
(4)将步骤(3)得到的浓缩煮液加入3倍重量的浓度为95%的乙醇,边加入边搅拌,静置24h,除去沉淀并回收乙醇,浓缩至每毫升注射水含生药2g,得到浓缩药液;
(5)滴加稀氢氧化钠使步骤(4)得到的浓缩药液的pH达到7.0,按所述浓缩药液重量的0.15%加入活性炭,煮沸25-30min,放置12h,再按所述浓缩药液重量的1%各加入苯甲醇和吐温-80,搅匀,G-3号垂熔玻璃漏斗过滤,滤液用注射水补足至每毫升注射水含生药2g,灌装,灭菌,即得本发明治疗猪蓝耳病的中草药注射液。
本发明组方中各组份药理功效是:
1.金银花功效:金银花为忍冬科忍冬属植物忍冬及同属植物干燥花蕾或初开的花。性甘、寒,气芳香。归肺,胃,心,大肠经。金银花含绿原酸,异绿原酸,白果醇,β-谷甾醇,豆甾醇,β-谷甾醇-D-葡萄糖甙,豆甾醇-D-葡萄糖甙。还含挥发油,其成分有芳樟醇,左旋-顺三甲基-2-乙烯基-5-羟基-四氢吡喃,棕榈酸乙酯,1,1-联二环已烷,亚油酸甲酯,3-甲基-2-(2-戊烯基)-2-环戊烯-1-酮,亚麻酸乙酯,顺-3-已烯-1-醇,α-松油醇,丁香油酚及香荆芥酚等数十种。所含成分氯原酸等有机酸及黄酮类物质,是其主要的抗菌有效成分。金银花水煎剂对流感病毒、孤儿病毒、疱疹病毒均有抑制作用,能抑制病毒的复制,延缓病毒所致细胞病变的发生,并有一定的抗炎解热、抗内毒素作用。此外,尚能促进白细胞吞噬能力,提高淋巴细胞转化率。具有清热解毒、疏散风热之功效。主治温病热入气分或营血,身发斑疹,热毒痈肿疮毒。
2.连翘功效:连翘又名黄花条、连壳、青翘、落翘、黄奇丹等。味苦,微寒。归肺、心、小肠经。含有连翘酚,连翘甙、连翘甙元,齐墩果酸、白桦脂酸、熊果酸、松脂素、马苔树脂醇甙,尚含有多种烃类、醛酮类、醇酯醚类挥发性成分如α-蒎烯、莰烯、β-蒎烯等,樟脑、香叶醛,龙脑、α-萜品醇、黄樟醚、芳樟醇、松油烯醇-4、去甲拉帕醇以及香豆素、芦丁等。连翘对多种革兰阳性及阴性细菌均有抑制作用。其浓缩煎剂在体外可抑制伤寒杆菌、副伤寒杆菌、大肠杆菌、痢疾杆菌、白喉杆菌及霍乱弧菌、葡萄球菌、链球菌等。体外实验表明连翘对亚洲甲型流感病毒、鼻病毒-17 型有抑制作用,连翘子挥发油在体外对金黄色葡萄球菌也有明显的抗菌作用,还有明显抑制金黄色葡萄球菌血浆凝固酶对血浆的凝固作用。有清热解毒,消肿散结之功效。用于痈疽,瘰疬,风热感冒,温病初起,温热入营,高热烦渴。主治热病初起,风热感冒,发热等。
3.黄芩功效:黄芩别名山茶根、黄芩茶、土金茶根等。为唇形科植物黄芩,以根入药。味苦,寒。归肺、胆、脾、大肠、小肠经。黄芩根含黄酮类化合物:黄芩素,黄芩新素,黄芩甙,汉黄芩素,汉黄芩甙,木蝴蝶素A,7-甲氧基黄芩素,二氢木蝴蝶素,白杨素,另外还含β-谷甾醇,菜油甾醇及豆甾醇等有效成分。对痢疾杆菌、大肠杆菌、变形杆菌、绿脓杆菌、葡萄球菌、溶血性琏球菌等有抑制作用。有清热燥湿,凉血安胎,解毒之功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾等症。
4.紫锥菊功效:紫锥菊含有多糖、黄酮、咖啡酸的衍生物、精油、多炔、烷基胺和生物碱。紫锥菊有免疫刺激作用,减少发炎,而且帮助机体对抗细菌和病毒。有关试验表明用紫锥菊饲喂动物,可提高嗜中性粒细胞的吞噬能力及外周淋巴细胞的数量,有效刺激动物机体的免疫活性;将紫锥菊根制成饲料添加剂喂鸡,可明显增加实验组体重和降低球虫的感染率。
5.黄芪功效:黄芪别称棉芪,黄耆,独椹,蜀脂,百本。味甘,微温。归肺,脾,肝,肾经。含皂甙、黄酮、多糖、多种氨基酸、叶酸及硒、锌、铜等多种微量元素,具有增强机体免疫功能、保肝、利尿、降压、抗衰老、抗缺氧、抗辐射、抗应激、耐低温和耐高温作用。动物试验证明,能够增加网状内皮系统的吞噬功能,促进抗体形成,提高E-玫瑰花环率,促进T细胞的分化与成熟,增强NK细胞的细胞毒活性,诱导产生干扰素;对细菌脂多糖诱导的鸡外周血B淋巴细胞体外增殖也有明显的促进作用;有加强毛细血管抵抗力的作用,可对抗组织胺、氯仿造成的毛细血管渗透性增加的现象。黄芪在体外对痢疾杆菌、溶血性链球菌、金黄色葡萄球菌等有较强的抗菌作用,对动物流感病毒、腺病毒等所致的细胞病变有抑制作用。有益气固表、敛汗固脱、托疮生肌、利水消肿之功效。用于治疗气虚乏力,中气下陷,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴等症。
本发明组方依据:本组方以扶正祛邪,增强猪抗病、防病能力,提高免疫力为原则。方中金银花、连翘为清热、解毒主药,黄芩为清热、解毒、抗菌、消炎辅药,紫锥菊具有免疫刺激作用,减少发炎,而且可帮助机体对抗细菌和病毒;黄芪有补中益气,生津养血,扶正祛邪,调节机体免疫功能。方中诸药相和,共奏清热解毒,抗菌消炎,提高机体免疫力和抗病能力的功效。为增强治疗效果,制成注射液。
本发明中草药注射液适用于由猪蓝耳病病毒及其因猪蓝耳病病毒感染引起的各种细菌的继发感染、药物使用不当等原因引起的免疫抑制。
本发明中草药注射液具有清热解毒、抗菌消炎功效,能增强猪抗病、防病能力,提高免疫力,作为治疗猪蓝耳病的中草药制剂,具有良好的效果。
具体实施方式
下面结合实施例对本发明作进一步说明。
实施例:
1、分别称取原料药(中草药饮片):金银花100 g,连翘200 g,黄芩100 g ,紫锥菊350 g,黄芪250 g;
2、将上述原料药分别粉碎成中草药粗粉;
3、将黄芩、黄芪两味中草药粗粉混合,加水7000 mL浸泡1 h,文火煎煮30 min,再放入金银花、连翘、紫锥菊中草药粗粉,文火煎煮30 min,得到第一次煮液,然后再每次加水5000 mL煎煮二次,每次煎煮30 min,得到第二次煮液和第三次煮液;
4、合并上述三次煮液,过滤,浓缩至每毫升注射水含生药1g,得到浓缩煮液,然后加入浓度为95%的乙醇1500 mL,边加入边搅拌,静置24h,去沉淀取上清液,蒸去乙醇,浓缩至每毫升注射水含生药2g,得到浓缩药液;
5、滴加稀氢氧化钠使上述浓缩药液的pH达到7.0,加该浓缩药液重量0.15%的活性炭煮沸30min,放置12h,过滤,按该浓缩药液重量各加入1%的苯甲醇和吐温-80,搅匀,G-3号垂榕玻璃漏斗过滤,滤液用注射水补足500mL,灌装每瓶10mL,100℃、30 min灭菌,即得本发明治疗猪蓝耳病的中草药注射液。
利用本发明进行的一些试验情况如下:
1、本发明中草药注射液对PRRSV的抑制作用
中药有效成分抗病毒作用的机理,一般认为主要有2条途径,一是直接杀灭病毒,二是抑制病毒的繁殖。本实验按抑制病毒的繁殖途径设计了1组试验,即先接种病毒后加本发明中草药注射液以观察中草药样品能否对细胞内的PRRSV起抑制作用,即抑制其生物合成及成熟释放。本发明中草药注射液对PRRSV的抑制作用测定实验是这样实现的:将100TCID50 PRRSV接种至长成单层猴胚胎肾上皮细胞(Marc-145)的96孔细胞培养板上,0.1 mL/孔,37℃吸附1.5 h,弃去PRRSV液,用磷酸盐缓冲液PBS 液洗2次,加入倍比稀释的单味中药和本发明中草药注射液,0.1 mL/孔,每个稀释度重复4孔,另设细胞对照和PRRSV对照,5% CO2培养箱37 ℃培养,结果见表1。试验结果表明,金银花、连翘、黄芩、紫锥菊、黄芪水提物对PRRSV在Marc-145细胞上的增殖具有明显的抑制作用,5种单味中药提取物分别在0.25 mg/mL、0.25 mg/mL、0.25 mg/mL、0.125 mg/mL浓度时仍具有显著的抑制CPE作用,其中紫锥菊水提物对PRRSV引起的细胞病变CPE最小抑制浓度最低,为0.0625 mg/mL;本发明中草药注射液对PRRSV引起的CPE最小抑制浓度也最低,为0.0625 mg/mL。
表1本发明中草药注射液对PRRSV在Marc-145细胞上增殖的抑制作用
注: -为正常Marc-145细胞;+为25% 的细胞出现细胞病变CPE;++为50%的细胞出现细胞病变CPE;+++为75%的细胞出现细胞病变CPE;++++为100%的细胞出现细胞病变CPE。
2、本发明中草药注射液对猪蓝耳病的治疗效果
2.1分组治疗:取经实验室诊断为猪蓝耳病病猪60头平均分成3组,分别放入3个隔离猪舍内。3个隔离猪舍内猪群分别为本发明中草药注射液组(20头),用本发明中草药注射液注射给药10 mL;干扰素组(20头),注射干扰素5 mL;抗生素对照组(20头),每头肌肉注射头孢噻肟钠1 支;以上各组均每天用药2次,连用5 d。另有空白对照组(10头)放在远离病猪群另一猪舍内,不给药。
2.2疗效判定:观察猪的精神、采食、体温、呼吸、皮肤和耳朵颜色及死亡等情况,按如下标准判断疗效。治愈:用药后呼吸平稳,精神、饮食、体温、皮肤和耳朵颜色恢复正常。好转:用药后症状明显减轻,呼吸、精神、体温、饮食好转。无效:用药后症状不减轻,甚至加重或死亡。总有效率=治愈率+好转率。
2.3治疗结果:本发明中草药注射液治愈率和总有效率均显著高于抗生素组和不治疗的空白对照组,但和干扰素组相比差异不显著,表明本发明中草药注射液对猪繁殖与呼吸综合征有疗效,各组的治疗效果见表2。
表2 各组的治疗效果(%)
| 项目 | 治愈率 | 好转率 | 总有效率 |
| 本发明中药注射液 | 60%(12/20) | 20% (4/20) | 80%(16/20) |
| 干扰素组 | 50% (10/20) | 25%(5/20) | 75%(15/20) |
| 抗生素组 | 30 %(6/20) | 10%(2/20) | 40%(8/20) |
| 空白对照组 | 0%(0/20) | 5% (1/20) | 5%(1/20) |
使用本发明中草药注射液治疗猪蓝耳病有较好的疗效,和干扰素相似,高于抗生素对照和空白对照。通过各项试验表明,本发明中草药注射液,对猪蓝耳病有明显的治疗效果。
Claims (3)
1.一种治疗猪蓝耳病的中草药注射液,其特征在于它是由下述重量配比的原料药制成:金银花1-2份,连翘2-4份,黄芩1-2份,紫锥菊6-8份,黄芪4-6份。
2.根据权利要求1所述的治疗猪蓝耳病的中草药注射液,其特征在于它是由下述重量配比的原料药制成:金银花2份,连翘4份,黄芩2份,紫锥菊7份,黄芪5份。
3.一种治疗猪蓝耳病的中草药注射液的制备方法,其特征在于它包括以下步骤:
(1)按重量配比分别称取金银花、连翘、黄芩、紫锥菊、黄芪中草药饮片,并分别粉碎成中草药粗粉;
(2)取黄芩、黄芪中草药粗粉,按步骤(1)得到的中草药粗粉总重量的7倍加注射水浸泡1-1.5h,加热煎煮25-35min,再加入金银花、连翘、紫锥菊中草药粗粉煎煮25-35 min,倾出第一次煮液,再按步骤(1)得到的中草药粗粉总重量的5倍加注射水煎煮两次,每次煎煮25-35min,得到第二次煮液和第三次煮液;
(3)合并步骤(2)得到的三次煮液,过滤,浓缩至每毫升注射水含生药1g,得到浓缩煮液;
(4)将步骤(3)得到的浓缩煮液加入3倍重量的浓度为95%的乙醇,边加入边搅拌,静置24h,除去沉淀并回收乙醇,浓缩至每毫升注射水含生药2g,得到浓缩药液;
(5)滴加稀氢氧化钠使步骤(4)得到的浓缩药液的pH达到7.0,按所述浓缩药液重量的0.15%加入活性炭,煮沸25-30min,放置12h,再按所述浓缩药液重量的1%各加入苯甲醇和吐温-80,搅匀,G-3号垂熔玻璃漏斗过滤,滤液用注射水补足至每毫升注射水含生药2g,灌装,灭菌,即得本发明治疗猪蓝耳病的中草药注射液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100916831A CN103142702A (zh) | 2013-03-21 | 2013-03-21 | 治疗猪蓝耳病的中草药注射液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100916831A CN103142702A (zh) | 2013-03-21 | 2013-03-21 | 治疗猪蓝耳病的中草药注射液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103142702A true CN103142702A (zh) | 2013-06-12 |
Family
ID=48541211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100916831A Pending CN103142702A (zh) | 2013-03-21 | 2013-03-21 | 治疗猪蓝耳病的中草药注射液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142702A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623192A (zh) * | 2013-12-13 | 2014-03-12 | 山东新希望六和集团有限公司 | 用于治疗猪蓝耳病的药物及其制备方法 |
| KR101478110B1 (ko) * | 2013-06-17 | 2014-12-31 | 한국생명공학연구원 | 돼지 호흡기 복합감염증 원인 세균에 대해 항균활성을 나타내는 우르솔산 및 이의 용도 |
| CN104800370A (zh) * | 2015-04-24 | 2015-07-29 | 河北科技师范学院 | 治疗猪蓝耳病的中草药注射液 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067985A1 (en) * | 2001-02-23 | 2002-09-06 | The Board Of Regents Of The University Of Nebraska | Method for prophylaxis and treatment of porcine reproductive and respiratory syndrome |
| CN101244146A (zh) * | 2008-02-22 | 2008-08-20 | 辽宁职业学院 | 治疗高致病性猪兰耳病中药针剂的制作方法 |
| CN101417008A (zh) * | 2008-10-31 | 2009-04-29 | 江西中成药业集团有限公司 | 作为中兽药复方制剂的注射用双黄连及其制备工艺与应用 |
| CN101869706A (zh) * | 2010-06-24 | 2010-10-27 | 西北农林科技大学 | 一种复方黄芪多糖和紫锥菊提取物纳米乳佐剂及其制备方法 |
| CN102228636A (zh) * | 2011-06-29 | 2011-11-02 | 北京康华远景科技有限公司 | 治疗高致病性蓝耳病的中药组合物 |
| CN102716164A (zh) * | 2012-06-28 | 2012-10-10 | 齐鲁动物保健品有限公司 | 一种紫锥菊提取物及其制备方法 |
| CN102772790A (zh) * | 2012-06-28 | 2012-11-14 | 齐鲁动物保健品有限公司 | 一种复方紫锥菊制剂及其制备方法和应用 |
-
2013
- 2013-03-21 CN CN2013100916831A patent/CN103142702A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067985A1 (en) * | 2001-02-23 | 2002-09-06 | The Board Of Regents Of The University Of Nebraska | Method for prophylaxis and treatment of porcine reproductive and respiratory syndrome |
| CN101244146A (zh) * | 2008-02-22 | 2008-08-20 | 辽宁职业学院 | 治疗高致病性猪兰耳病中药针剂的制作方法 |
| CN101417008A (zh) * | 2008-10-31 | 2009-04-29 | 江西中成药业集团有限公司 | 作为中兽药复方制剂的注射用双黄连及其制备工艺与应用 |
| CN101869706A (zh) * | 2010-06-24 | 2010-10-27 | 西北农林科技大学 | 一种复方黄芪多糖和紫锥菊提取物纳米乳佐剂及其制备方法 |
| CN102228636A (zh) * | 2011-06-29 | 2011-11-02 | 北京康华远景科技有限公司 | 治疗高致病性蓝耳病的中药组合物 |
| CN102716164A (zh) * | 2012-06-28 | 2012-10-10 | 齐鲁动物保健品有限公司 | 一种紫锥菊提取物及其制备方法 |
| CN102772790A (zh) * | 2012-06-28 | 2012-11-14 | 齐鲁动物保健品有限公司 | 一种复方紫锥菊制剂及其制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| 韩公羽等: "《中国人最应知道的植物药有效成分》", 31 March 2009, article "紫锥菊", pages: 144-145 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101478110B1 (ko) * | 2013-06-17 | 2014-12-31 | 한국생명공학연구원 | 돼지 호흡기 복합감염증 원인 세균에 대해 항균활성을 나타내는 우르솔산 및 이의 용도 |
| CN103623192A (zh) * | 2013-12-13 | 2014-03-12 | 山东新希望六和集团有限公司 | 用于治疗猪蓝耳病的药物及其制备方法 |
| CN104800370A (zh) * | 2015-04-24 | 2015-07-29 | 河北科技师范学院 | 治疗猪蓝耳病的中草药注射液 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100431581C (zh) | 治疗禽流感的中药组合物、制备方法及其用途 | |
| CN103271102A (zh) | 奶牛场用中草药环保消毒剂 | |
| CN102552502B (zh) | 一种用于禽细菌性疾病的中药 | |
| CN102091151B (zh) | 具有疏风祛湿功能的中药组合物及其制备方法 | |
| CN104887890A (zh) | 一种治疗雏鸡白痢的药物组合物及其制备方法 | |
| CN109549973A (zh) | 一种具有治疗和预防畜禽疾病的中药组合物、及其制备方法和应用 | |
| CN105168807B (zh) | 治疗猪蓝耳病的中药组合物及其制备方法 | |
| CN102648944A (zh) | 一种治疗鸡传染性鼻炎的中药组合物及其制备方法 | |
| CN107158087A (zh) | 一种预防猪瘟病的中药组合物及其制备方法 | |
| CN102698158B (zh) | 防治鸡肾型传染性支气管炎的中药、制备方法和饲料 | |
| CN103142702A (zh) | 治疗猪蓝耳病的中草药注射液及其制备方法 | |
| CN104800370A (zh) | 治疗猪蓝耳病的中草药注射液 | |
| CN103211985B (zh) | 鸭传染性浆膜炎的治疗中药 | |
| WO2020155318A1 (zh) | 一种治疗家畜细菌性呼吸道疫病的中药制剂及其生产工艺 | |
| CN103494927A (zh) | 一种用于治疗鸡呼吸道疾病的中药组合物及其制备方法 | |
| CN109432287B (zh) | 一种防治家禽气分热盛证的中药口服液及其制备方法 | |
| CN102228607B (zh) | 一种用于治疗猪无名高热病的口服液 | |
| CN107582650A (zh) | 一种用于防治母猪乳腺炎的中药组合物 | |
| CN106822536B (zh) | 一种治疗猪弓形虫病的中药组合物及其制备方法与应用 | |
| CN111760004B (zh) | 一种防治畜禽流感的中药颗粒及应用 | |
| CN111588801B (zh) | 一种预防畜禽疫病的中药分散颗粒剂及其制备方法 | |
| CN113209011A (zh) | 防治猪病毒性腹泻疾病的中药口服液及其制备方法和应用 | |
| CN107753596A (zh) | 一种组合物、其制备方法、中药制剂及用途 | |
| CN106729589A (zh) | 治疗猪传染性胃肠炎的中药制剂及制备方法 | |
| CN108465098B (zh) | 一种防治家禽新城疫病的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130612 |